Fakih, Marwan GMarwan GFakihSalvatore, LisaLisaSalvatoreEsaki, TaitoTaitoEsakiModest, Dominik PDominik PModestLopez-Bravo, David PDavid PLopez-BravoTaieb, JulienJulienTaiebKaramouzis, Michalis VMichalis VKaramouzisRuiz-Garcia, ErikaErikaRuiz-GarciaKim, Tae-WonTae-WonKimKuboki, YasutoshiYasutoshiKubokiMeriggi, FaustoFaustoMeriggiCunningham, DavidDavidCunninghamKUN-HUEI YEHChan, EmilyEmilyChanChao, JosephJosephChaoSaportas, YanethYanethSaportasTran, QuiQuiTranCremolini, ChiaraChiaraCremoliniPietrantonio, FilippoFilippoPietrantonio2024-03-282024-03-282023-12-0700284793https://scholars.lib.ntu.edu.tw/handle/123456789/641515KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy.en[SDGs]SDG3journal article10.1056/NEJMoa2308795378709682-s2.0-85175486939https://api.elsevier.com/content/abstract/scopus_id/85175486939